Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:18 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:18 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Illumina Fettered With Losses: Can It Bounce Back in 2017?
by Zacks Equity Research
During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.
Masimo to Launch Advanced Monitoring Technologies in India
by Zacks Equity Research
Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?
by Zacks Equity Research
On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).
Is Baxter Poised to Counter Low Cyclophosphamide Sales?
by Zacks Equity Research
On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions
by Zacks Equity Research
On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege
by Zacks Equity Research
Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite
by Zacks Equity Research
NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.
LabCorp: Covance Drug Prospects Bright, Competition Rife
by Zacks Equity Research
On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).
ResMed: SDB Business Faces Risks, Reimbursement a Drag
by Zacks Equity Research
On Dec 27, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Nutrisystem Declares Multi-Brand Marketing Approach for '17
by Zacks Equity Research
Nutrisystem Inc. (NTRI) announced that it will focus on a multi-brand marketing approach with two new distinct programs.
What's in Store for Walgreens Boots (WBA) in Q1 Earnings?
by Zacks Equity Research
Walgreens Boots Alliance, Inc (WBA) is slated to release first-quarter 2017 results, before the market opens on Jan 5.
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger
by Zacks Equity Research
On Dec 27, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Align Technology Hits 52-Week High on Q3 & Dental Strength
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) scaled a new 52-week high of $102.1 on Dec 19, finally closing a bit lower at $100.3.
Align Up on Balanced Growth, Expansion of Invisalign Teen
by Zacks Equity Research
On Dec 9, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Zacks.com featured highlights: Movado Group, Align Technology, Arch Capital Group, Gibraltar Industries and Rogers
by Zacks Equity Research
Zacks.com featured highlights: Movado Group, Align Technology, Arch Capital Group, Gibraltar Industries and Rogers
Think Like Driehaus and Invest in These Stocks
by Zacks Equity Research
"Buy high and sell higher" is the basic principle of most momentum strategies.
Top Ranked Momentum Stocks to Buy for December 1st
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, December 1st:
New Strong Buy Stocks for December 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Bull of the Day: Align Technology (ALGN)
by Eric Dutram
Things are lining up nicely for a beat in this stock when it reports earnings later this month thanks to rising estimates.